# US 2021/0332080 A1 · Hydrophilic linkers for antibody drug conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332080 A1
- Document ID: US20210332080A1
- Status: Published application
- Kind: A1
- Application number: 16/761,493
- Filed: 2018-11-06
- Published: 2021-10-28
- Earliest claimed: 2017-11-07
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Amy HAN
- Web page: https://patentgrep.com/patent/US20210332080A1

## CPC

- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 31/566: having an oxo group in position 17, e.g. estrone
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/554: {the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid}
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K 47/6801: {Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07J 41/005: {the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives}
- C07J 41/0088: {containing unsubstituted amino radicals}
- C07J 71/0026: {cyclic ketals}
- C07J 71/0031: {at positions 16, 17}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07J: STEROIDS (seco-steroids C07C)

## Abstract

Described herein protein drug conjugates and compositions thereof that are useful, for example, for the target-specific delivery of drugs to cells. By administering these compounds, compositions, and conjugates as described herein to specific target cells, side-effects due to non-specific binding phenomena, for example, to non-target cells are reduced. In certain embodiments, compounds, compositions, and conjugates are provided, which include hydrophilic residues in linker-payloads and protein conjugates thereof.

## Claims

### Claim 1

A compound, or pharmaceutically acceptable solvate, stereoisomer, or derivative thereof, comprising a binding agent linked to at least one payload moiety and linked to at least one hydrophilic residue via a covalent linker, wherein the said covalent linker is bonded directly or indirectly to each of the binding agent, the payload moiety, and the hydrophilic residue.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the hydrophilic residue comprises a terminal hydrophilic group.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the hydrophilic residue comprises a sulfonic acid group or a salt thereof.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the hydrophilic residue comprises a quarternary amine or a salt thereof, a phosphonic acid group or a salt thereof, or a sugar residue.

### Claim 5 (depends on 1)

The compound of claim 1, according to Formula (I):
or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof,
wherein:
BA is a binding agent;
L is a trivalent linker;
HL is a hydrophilic residue;
PA is a payload residue; and
subscript n is an integer from 1 to 30.

### Claim 6 (depends on 5)

The compound of claim 5, according to Formula (II):
wherein:
BA is a binding agent;
LL is a trivalent linker;
RG1 and RG2 are reactive group residues;
SP1 and SP2 are independently, in each instance, absent, or a spacer group residue;
HG is a hydrophilic residue;
PA is a payload residue;
subscript n is an integer from 1 to 30; and
subscript q is 0 or 1.

### Claim 7 (depends on 5)

The compound of claim 5, wherein subscript n is 1, 2, 3 or 4.

### Claim 8 (depends on 5)

The compound of claim 5, according to Formula (III):
wherein
ring A is fused to the triazole and is selected from the group consisting of cycloalkyl, cycloalkenyl, heterocycloalkyl, and heterocycloalkenyl;
wherein cycloalkyl, cycloalkenyl, heterocycloalkyl, and heterocycloalkenyl are optionally substituted with alkyl, —OH, or —NRaRb, where each of Ra and Rb is alkyl or H.

### Claim 9 (depends on 6)

The compound of claim 6, according to Formula (IV):
wherein:
AA1 is a trivalent linker comprising an amino acid residue;
AA2 is a dipeptide, tripeptide, or tetrapeptide residue; and
PAB is
wherein the
indicates the atom through which the PAB is bonded to the adjacent groups in the formula;
subscript p is 0 or 1; and
subscript q is 0 or 1.

### Claim 10 (depends on 9)

The compound of claim 9, according to Formula (IVa), Formula (IVb) or Formula (IVc):

### Claim 11 (depends on 10)

The compound of claim 10, wherein AA1 is lysine, glutamine, glutamic acid, or aspartic acid.

### Claim 12 (depends on 10)

The compound of claim 10, according to Formula (Va), (Vb), (Vc) or (Vd) respectively:
wherein:
subscript e is independently, in each instance, an integer from 0 to 6.

### Claim 13 (depends on 9)

The compound of claim 9, wherein RG1 and RG2 are independently in each instance, a click chemistry residue.

### Claim 14 (depends on 9)

The compound of claim 9, wherein RG1 and RG2 independently in each instance, comprise a triazaole or a fused triazole.

### Claim 15 (depends on 9)

The compound of claim 9, wherein RG1 and RG2 are independently, in each instance, selected from the group consisting of
wherein the
indicates the atom through which the RG1 or RG2 is bonded to the adjacent groups in the formula.

### Claim 16 (depends on 9)

The compound of claim 9, wherein HG is
wherein the
indicates the atom through which the HG is bonded to the adjacent groups in the formula.

### Claim 17 (depends on 9)

The compound of claim 9, wherein HG is
wherein the
indicates the atom through which the HG is bonded to the adjacent groups in the formula.

### Claim 18 (depends on 9)

The compound of claim 9, wherein HG is
wherein the
indicates the atom through which the HG is bonded to the adjacent groups in the formula.

### Claim 19 (depends on 9)

The compound of claim 9, wherein HG is
wherein the
indicates the atom through which the HG is bonded to the adjacent groups in the formula.

### Claim 20 (depends on 9)

The compound of claim 9, wherein SP1 and SP2 are independently, in each instance, absent, or selected from the group consisting of C1-6 alkylene, —NH—, —C(O)—, (—CH2—CH2—O)e, —NH—CH2—CH2—(—O—CH2—CH2)e—C(O)—, —C(O)—(CH2)u—C(O)—, —C(O)—NH—(CH2)v—, (glycine)4-serine, and combinations thereof, wherein subscript e is an integer from 0 to 4, subscript u is an integer from 1 to 8, and subscript v is an integer from 1 to 8.

### Claim 21 (depends on 9)

The compound of claim 9, wherein
is selected from the group consisting of:
or a stereoisomeric form thereof, or a regioisomer thereof, or a mixture of regioisomers thereof, wherein
each
is a bond to the binding agent; and
each
is a bond to the payload residue.

### Claim 22 (depends on 9)

The compound of claim 9, wherein
is selected from the group consisting of:
or a stereoisomeric form thereof, or a regioisomer thereof, or a mixture of regioisomers thereof, wherein
each
is a bond to the binding agent; and
each
is a bond to the payload residue.

### Claim 23 (depends on 6)

The compound of claim 6, wherein LL is according to Formula (LL1):
wherein RAA1, RAA2, and RAA3 are each, independently, amino acid side chains, at least one of which is bonded directly or indirectly to —(RG2)q—SP2-HG

### Claim 24 (depends on 23)

The compound of claim 23, wherein RAA1 is a lysine, glutamine, glutamic acid or aspartic acid side chain bonded directly or indirectly to HG, and RAA2 and RAA3 are either valine and alanine or valine and citrulline sidechains respectively.

### Claim 25 (depends on 9)

The compound of claim 9, wherein AA2 is
wherein RAA2, RAA3, RAA4, and RAA5 are each, independently, amino acid side chains, at least one of which is bonded directly or indirectly to —(RG2)q—SP2-HG, wherein the
indicates the atom through which AA2 is bonded to the adjacent groups in the formula.

### Claim 26 (depends on 9)

The compound of claim 9, wherein AA2 is
wherein
the indicates the atom through which AA2 is bonded to the adjacent groups in the formula.

### Claim 27 (depends on 12)

The compound of claim 12, wherein subscript e is 4.

### Claim 28 (depends on 1)

The compound of any claim 1, wherein the binding agent (BA) is an antibody or antigen-binding fragment thereof.

### Claim 29 (depends on 1)

The compound of any claim 1, wherein the binding agent (BA) is an antibody, or an antigen-binding fragment thereof, selective for an antigen selected from the group consisting of AXL, BAFFR, BCMA, BCR-list components, BDCA2, BDCA4, BTLA, BTNL2, BTNL3, BTNL8, BTNL9, C10 or f54, CCR1, CCR3, CCR4, CCR5, CCR6, CCR7, CCR9, CCR10, CD11c, CD137, CD138, CD14, CD168, CD177, CD19, CD20, CD209, CD209L, CD22, CD226, CD248, CD25, CD27, CD274, CD276, CD28, CD30, CD300A, CD33, CD37, CD38, CD4, CD40, CD44, CD45, CD46, CD48, CD5, CD52, CD55, CD56, CD59, CD62E, CD68, CD69, CD70, CD74, CD79a, CD79b, CD8, CD80, CD86, CD90.2, CD96, CLEC12A, CLEC12B, CLEC7A, CLEC9A, CR1, CR3, CRTAM, CSF1R, CTLA4, CXCR1/2, CXCR4, CXCR5, DDR1, DDR2, DEC-205, DLL4, DR6, FAP, FCamR, FCMR, FcR's, Fire, GITR, HHLA2, HLA class II, HVEM, ICOSLG, IFNLR1, IL10R1, IL10R2, IL12R, IL13RA1, IL13RA2, IL15R, IL17RA, IL17RB, IL17RC, IL17RE, IL20R1, IL20R2, IL21R, IL22R1, IL22RA, IL23R, IL27R, IL29R, IL2Rg, IL31R, IL36R, IL3RA, IL4R, IL6R, IL5R, IL7R, IL9R, Integrins, LAG3, LIFR, MAG/Siglec-4, MMR, MSR1, NCR3LG1, NKG2D, NKp30, NKp46, PDCD1, PROKR1, PVR, PVRIG, PVRL2, PVRL3, RELT, SIGIRR, Siglec-1, Siglec-10, Siglec-5, Siglec-6, Siglec-7, Siglec-8, Siglec-9, SIRPA, SLAMF7, TACI, TCR-list components/assoc, PTCRA, TCRb, CD3z, CD3, TEK, TGFBR1, TGFBR2, TGFBR3, TIGIT, TLR2, TLR4, TROY, TSLPR, TYRO, VLDLR, VSIG4, and VTCN1.

### Claim 30 (depends on 1)

The compound of any claim 1, wherein PA is the residue of a group selected from the group consisting of a dolastatin, an auristatin, a maytansinoid, a plant alkaloid, a taxane, a vinca alkaloid, a steroid, and a liver X receptor (LXR) modulator.

### Claim 31 (depends on 1)

The compound of any claim 1, selected from the group consisting of:
or a stereoisomeric form thereof, or a regioisomer thereof, or a mixture of regioisomers thereof, wherein
each Ab is an antibody, or an antigen-binding fragment thereof;
PA is a payload residue; and
subscript n is an integer from 1 to 30.

### Claim 32 (depends on 1)

The compound of any claim 1, selected from the group consisting of:
or a stereoisomeric form thereof, or a regioisomer thereof, or a mixture of regioisomers thereof, wherein
each Ab is an antibody, or an antigen-binding fragment thereof; and
subscript n is an integer from 1 to 30.

### Claim 33 (depends on 1)

The compound of any claim 1, wherein BA is a modified antibody of formula (Ab-1)
wherein the
indicates the atom through which Ab-1 is bonded to the adjacent groups in the formula.

### Claim 34 (depends on 1)

The compound of any claim 1, selected from the group consisting of:
or a stereoisomeric form thereof, or a regioisomer thereof, or a mixture of regioisomers thereof, wherein
each Ab is an antibody, or an antigen-binding fragment thereof; and
subscript n is an integer from 1 to 30.

### Claim 35 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 36 (depends on 1)

A method of treating a disease or disorder in a patient in need thereof comprising administering to the patient a compound of claim 1.

### Claim 37

A compound comprising a reactive linker bonded to at least one payload moiety and bonded to at least one hydrophilic residue via a covalent linker, wherein said covalent linker is bonded directly or indirectly to each of the reactive linker, the payload moiety, and the hydrophilic residue.

### Claim 38 (depends on 37)

The compound of claim 37, according to Formula (VI):
or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof, wherein:
RG′ is a reactive group;
L is a trivalent linker;
HL is a hydrophilic residue; and
PA is a payload residue.

### Claim 39 (depends on 38)

The compound of claim 38, according to Formula (VII):
wherein:
LL is a trivalent linker;
RG′ is a reactive group;
RG2 is a reactive group residue;
SP1 and SP2 are independently, in each instance, absent, or a spacer group residue;
HG is a hydrophilic residue;
PA is a payload residue; and
subscript q is 0 or 1.

### Claim 40 (depends on 39)

The compound of claim 39, according to Formula (VIII):
wherein
ring A is fused to the triazole and is selected from the group consisting of cycloalkyl, cycloalkenyl, heterocycloalkyl, and heterocycloalkenyl;
wherein cycloalkyl, cycloalkenyl, heterocycloalkyl, and heterocycloalkenyl are optionally substituted with alkyl, —OH, or —NRaRb, where each of Ra and Rb is alkyl or —H.

### Claim 41 (depends on 39)

The compound of claim 39, according to Formula (IX):
wherein:
AA1 is a trivalent linker comprising an amino acid residue;
AA2 is a dipeptide, tripeptide or tetrapeptide residue; and
PAB is
wherein the
indicates the atom through which the PAB is bonded to the adjacent groups in the formula;
subscript p is 0 or 1; and
subscript q is 0 or 1.

### Claim 42 (depends on 41)

The compound of claim 41, according to Formula (IXa), Formula (IXb) or Formula (IXc):

### Claim 43 (depends on 42)

The compound according to claim 42, wherein AA1 is lysine, glutamine, glutamic acid, or aspartic acid.

### Claim 44 (depends on 42)

The compound of claim 42, according to Formula (Xa), (Xb), (Xc), or (Xd):
wherein:
subscript e is independently, in each instance, an integer from 0 to 6.

### Claim 45 (depends on 38)

The compound of claim 38, wherein RG′ is, independently in each instance, a click chemistry residue.

### Claim 46 (depends on 38)

The compound of claim 38, wherein RG′ is, independently in each instance, selected from the group consisting of
wherein the
indicates the atom through which the RG1 is bonded to the adjacent groups in the formula.

### Claim 47 (depends on 38)

The compound of claim 38, wherein RG2 is independently, in each instance, selected from the group consisting of
wherein the
indicates the atom through which the RG2 is bonded to the adjacent groups in the formula.

### Claim 48 (depends on 39)

The compound of claim 39, wherein HG is
wherein
the
indicates the atom through which the HG is bonded to the adjacent groups in the formula.

### Claim 49 (depends on 39)

The compound of claim 39, wherein HG is
wherein the
indicates the atom through which the HG is bonded to the adjacent groups in the formula.

### Claim 50 (depends on 39)

The compound of claim 39, wherein HG is
wherein the
indicates the atom through which the HG is bonded to the adjacent groups in the formula.

### Claim 51 (depends on 39)

The compound of claim 39,
wherein HG is
wherein the
indicates the atom through which the HG is bonded to the adjacent groups in the formula.

### Claim 52 (depends on 39)

The compound of claim 39, wherein SP1 and SP2 are independently, in each instance, absent, or selected from the group consisting of C1-6 alkylene, —NH—, —C(O)—, (—CH2—CH2—O)e, —NH—CH2—CH2—(—O—CH2—CH2)e—C(O)—, —C(O)—(CH2)u—C(O)—, —C(O)—NH—(CH2)v—, (glycine)4-serine, and combinations thereof, wherein subscript e is an integer from 0 to 4, subscript u is an integer from 1 to 8, and subscript v is an integer from 1 to 8.

### Claim 53 (depends on 39)

The compound of claim 39, wherein
is selected from the group consisting of:
or a stereoisomeric form thereof, or a regioisomer thereof, or a mixture of regioisomers thereof, wherein
each
is a bond to the payload residue.

### Claim 54 (depends on 39)

The compound of claim 39, wherein
is selected from the group consisting of:
or a stereoisomeric form thereof, or a regioisomer thereof, or a mixture of regioisomers thereof, wherein
each
is a bond to the payload residue.

### Claim 55 (depends on 39)

The compound of claim 39, wherein LL is according to Formula (LL1):
wherein RAA1, RAA2, and RAA3 are each, independently, amino acid side chains, at least one of which is bonded directly or indirectly to —(RG2)q—SP2-HG

### Claim 56 (depends on 55)

The compound of claim 55, wherein RAA1 is a lysine, glutamine, glutamic acid or aspartic acid side chain bonded directly or indirectly to HG, and RAA2 and RAA3 are either valine and alanine or valine and citrulline sidechains respectively.

### Claim 57 (depends on 41)

The compound of claim 41, wherein AA2 is
wherein RAA2, RAA3, RAA4, and RAA5 are each, independently, amino acid side chains, at least one of which is bonded directly or indirectly to —(RG2)q—SP2-HG, wherein the
indicates the atom through which AA2 is bonded to the adjacent groups in the formula.

### Claim 58 (depends on 41)

The compound of claim 41, wherein AA2 is
wherein the
indicates the atom through which AA2 is bonded to the adjacent groups in the formula.

### Claim 59 (depends on 44)

The compound of claim 44, wherein subscript e is 4.

### Claim 60 (depends on 37)

The compound of claim 37, wherein PA is the residue of a group selected from the group consisting of a dolastatin, an auristatin, a maytansinoid, a plant alkaloid, a taxane, a vinca alkaloid, a steroid, and a liver X receptor (LXR) modulator.

### Claim 61 (depends on 37)

The compound of claim 37, selected from the group consisting of:
or a stereoisomeric form thereof, or a regioisomer thereof, or a mixture of regioisomers thereof, wherein PA is a payload residue.

### Claim 62 (depends on 37)

The compound of claim 37, selected from the group consisting of:
or a stereoisomeric form thereof, or a regioisomer thereof, or a mixture of regioisomers thereof.

### Claim 63 (depends on 37)

A method of preparing a compound comprising the step of contacting a binding agent with a compound according to claim 37, under conditions suitable for forming a bond between the binding agent and the compound.

### Claim 64 (depends on 63)

The method of claim 63, wherein the binding agent is a modified binding agent comprising an azido group
wherein the
indicates the atom through which the azido group is bonded to the adjacent groups in the formula.

### Claim 65 (depends on 37)

A linker-payload comprising the compound of claim 37, bonded to a linker.

### Claim 66 (depends on 37)

A linker-payload comprising the compound of claim 37, bonded to an oxygen or a primary or secondary nitrogen of the payload.

### Claim 67

An antibody-drug-conjugate comprising the compound or linker-payload of any of the preceding claims bonded to an antibody, or an antigen binding fragment thereof.

### Claim 68 (depends on 1)

A method of treating a proliferative disease, a metabolic disease, inflammation, or a neurodegenerative disease in a subject comprising administering to the subject an effective treatment amount of a compound of claim 1.

### Claim 69 (depends on 1)

A method for the treatment of a disease, disorder, or condition in a subject comprising administering to the subject an effective treatment amount of a compound of claim 1.

### Claim 70 (depends on 1)

A method for the treatment of a proliferative disease in a subject comprising administering to the subject an effective treatment amount of a compound of claim 1.

### Claim 71 (depends on 1)

A method for the treatment of a metabolic disease in a subject comprising administering to the subject an effective treatment amount of a compound of claim 1.

### Claim 72 (depends on 1)

A method for the treatment of inflammation in a subject comprising administering to the subject an effective treatment amount of a compound of claim 1.

### Claim 73 (depends on 1)

A method for the treatment of a neurodegenerative disease in a subject comprising administering to the subject an effective treatment amount of a compound of claim 1.
